KIMBERLY MILES: Open Payments
NPI 1811602469 · TROY, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$778 in 27 payments from 7 companies in 2025. Trend: 2023 $260 · 2024 $187 · 2025 $778
Food & beverage: $778
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $218 |
| Alkermes, Inc. | 7 | $201 |
| Vanda Pharmaceuticals Inc. | 4 | $171 |
| Neurocrine BioSciences, Inc. | 6 | $103 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
| E.R. Squibb & Sons, L.L.C. | 1 | $15 |
Products named: CAPLYTA, FANAPT, ARISTADA, INGREZZA, LYBALVI, AUSTEDO XR, INVEGA SUSTENNA, COBENFY.
Industry payments across AL — which companies pay providers there.
